A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITP

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2019

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
Eltrombopag is an oral thrombopoietin receptor agonist that has been licensed for use as second line therapy in ITP patients. Diacerein is a slow-acting medicine of the class anthraquinone used to treat joint diseases such as osteoarthritis. The project was undertaking by Qilu Hospital of Shandong University and other 5 well-known hospitals in China. In order to report the efficacy and safety of eltrombopag combined with diacerein in the management of ITP.
Epistemonikos ID: cc385365973a21715e7a140962a22df334bf925a
First added on: May 21, 2024